Exact Sciences (EXAS) announced the launch of Cologuard Plus, which it calls “the most accurate noninvasive colorectal cancer screening test reported in studies to date.” The company added: “FDA-approved for average-risk patients 45+ and covered by Medicare, the Cologuard Plus test detects 95% of colorectal cancers at 94% specificity in the U.S. screening population. This performance means fewer unnecessary follow-up colonoscopies – up to a 40% reduction compared to the original Cologuard test – and greater confidence in results.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences Positioned for Growth with Upcoming Product Launches and Margin Expansion
- Exact Sciences price target lowered to $60 from $73 at Guggenheim
- Exact Sciences: Strong Buy Rating Backed by Strategic Growth Initiatives and Favorable Market Positioning
- Exact Sciences initiated with a Sector Perform at RBC Capital
- Exact Sciences: Promising Growth with Cologuard Plus and New Product Launches